Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
Main Author: | |
---|---|
Publication Date: | 2020 |
Other Authors: | , |
Format: | Article |
Language: | eng |
Source: | Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
Download full: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503 |
Summary: | Botulinum toxin type A has been approved for spasticity management in poststroke patients. The adverse effects are generally of two types: those related to local injection; and those related to the systemic effects from spread of the toxin. Contralateral weakness after botulinum toxin A treatment is a rarely reported adverse effect. We report the case of a 33-year-old female who had been receiving regular injections of incobotulinum toxin A due to spasticity of the right limbs after a hemorrhagic stroke. A switch was made to abobotulinum toxin A with an overall conversion ratio of 1:3.83. The patient presented contralateral upper limb paresis, especially of the deltoid muscle, in the second week post-injection. The electroneuromyography showed neuromuscular block due to botulinum toxin A. She recovered completely after eight months. A switch between different formulations of botulinum toxin type A should prompt caution when carrying out unit conversions. Distant side effects may appear, including paresis in the contralateral limbs. |
id |
RCAP_1ff6edd85e0508aac898042f765e523d |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/11503 |
network_acronym_str |
RCAP |
network_name_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
repository_id_str |
https://opendoar.ac.uk/repository/7160 |
spelling |
Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke SpasticityParesia do Membro Superior Contralateral Após Infiltração de Toxina Botulínica A para Espasticidade Pós-AVCBotulinum ToxinsType A/adverse effectsMuscle Weakness/etiologyUpper ExtremityFraqueza Muscular/etiologiaMembros SuperioresToxinas Botulínicas Tipo A/efeitos adversosBotulinum toxin type A has been approved for spasticity management in poststroke patients. The adverse effects are generally of two types: those related to local injection; and those related to the systemic effects from spread of the toxin. Contralateral weakness after botulinum toxin A treatment is a rarely reported adverse effect. We report the case of a 33-year-old female who had been receiving regular injections of incobotulinum toxin A due to spasticity of the right limbs after a hemorrhagic stroke. A switch was made to abobotulinum toxin A with an overall conversion ratio of 1:3.83. The patient presented contralateral upper limb paresis, especially of the deltoid muscle, in the second week post-injection. The electroneuromyography showed neuromuscular block due to botulinum toxin A. She recovered completely after eight months. A switch between different formulations of botulinum toxin type A should prompt caution when carrying out unit conversions. Distant side effects may appear, including paresis in the contralateral limbs.A toxina botulínica A foi aprovada para o tratamento da espasticidade em doentes pós-AVC. Os efeitos adversos são geralmente de dois tipos: efeitos adversos relacionados com a administração local de toxina botulínica A; e efeitos adversos sistémicos relacionados com a difusão à distância da toxina. A paresia muscular dos membros contralaterais após tratamento com toxina botulínica A é um efeito adverso raro. Descrevemos o caso de uma mulher de 33 anos de idade que recebia infiltrações regulares de toxina incobotulínica A por espasticidade dos membros direitos pós-AVC hemorrágico. Foi feita uma troca para toxina abobotulínica A com um factor de conversão global de 1:3,83. A doente apresentou parésia do membro superior contralateral, especialmente do músculo deltóide. A electroneuromiografia foi compatível com bloqueio neuromuscular devido a toxina botulínica A. Recuperou totalmente após oito meses. A troca entre diferentes formulações de toxina botulínica A deve exigir precaução na conversão das unidades. Efeitos adversos à distância podem surgir, incluindo parésia dos membros contralaterais.Ordem dos Médicos2020-11-02info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfapplication/pdfapplication/pdfapplication/mswordapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503oai:ojs.www.actamedicaportuguesa.com:article/11503Acta Médica Portuguesa; Vol. 33 No. 11 (2020): November; 761-764Acta Médica Portuguesa; Vol. 33 N.º 11 (2020): Novembro; 761-7641646-07580870-399Xreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAPenghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/5804https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/10908https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/10909https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/11382https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/11414Direitos de Autor (c) 2019 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessCamões- Barbosa, AlexandreRibeiro, Inês MendesMedeiros, Luisa2022-12-20T11:06:16Zoai:ojs.www.actamedicaportuguesa.com:article/11503Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T10:41:26.569819Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse |
dc.title.none.fl_str_mv |
Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity Paresia do Membro Superior Contralateral Após Infiltração de Toxina Botulínica A para Espasticidade Pós-AVC |
title |
Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity |
spellingShingle |
Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity Camões- Barbosa, Alexandre Botulinum Toxins Type A/adverse effects Muscle Weakness/etiology Upper Extremity Fraqueza Muscular/etiologia Membros Superiores Toxinas Botulínicas Tipo A/efeitos adversos |
title_short |
Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity |
title_full |
Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity |
title_fullStr |
Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity |
title_full_unstemmed |
Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity |
title_sort |
Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity |
author |
Camões- Barbosa, Alexandre |
author_facet |
Camões- Barbosa, Alexandre Ribeiro, Inês Mendes Medeiros, Luisa |
author_role |
author |
author2 |
Ribeiro, Inês Mendes Medeiros, Luisa |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Camões- Barbosa, Alexandre Ribeiro, Inês Mendes Medeiros, Luisa |
dc.subject.por.fl_str_mv |
Botulinum Toxins Type A/adverse effects Muscle Weakness/etiology Upper Extremity Fraqueza Muscular/etiologia Membros Superiores Toxinas Botulínicas Tipo A/efeitos adversos |
topic |
Botulinum Toxins Type A/adverse effects Muscle Weakness/etiology Upper Extremity Fraqueza Muscular/etiologia Membros Superiores Toxinas Botulínicas Tipo A/efeitos adversos |
description |
Botulinum toxin type A has been approved for spasticity management in poststroke patients. The adverse effects are generally of two types: those related to local injection; and those related to the systemic effects from spread of the toxin. Contralateral weakness after botulinum toxin A treatment is a rarely reported adverse effect. We report the case of a 33-year-old female who had been receiving regular injections of incobotulinum toxin A due to spasticity of the right limbs after a hemorrhagic stroke. A switch was made to abobotulinum toxin A with an overall conversion ratio of 1:3.83. The patient presented contralateral upper limb paresis, especially of the deltoid muscle, in the second week post-injection. The electroneuromyography showed neuromuscular block due to botulinum toxin A. She recovered completely after eight months. A switch between different formulations of botulinum toxin type A should prompt caution when carrying out unit conversions. Distant side effects may appear, including paresis in the contralateral limbs. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-11-02 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503 oai:ojs.www.actamedicaportuguesa.com:article/11503 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/11503 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/5804 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/10908 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/10909 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/11382 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/11414 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2019 Acta Médica Portuguesa info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2019 Acta Médica Portuguesa |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf application/msword application/pdf |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 33 No. 11 (2020): November; 761-764 Acta Médica Portuguesa; Vol. 33 N.º 11 (2020): Novembro; 761-764 1646-0758 0870-399X reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia instacron:RCAAP |
instname_str |
FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
collection |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
repository.name.fl_str_mv |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
repository.mail.fl_str_mv |
info@rcaap.pt |
_version_ |
1833591128610308096 |